| Detected | Trial | Change |
|---|---|---|
| 2026-06-09 | NCT07405164 Extension Study for Participants in Studies That Include Belzutifan… |
Trial sites expanded: 15 -> 20 locations |
| 2026-06-06 | NCT06377852 The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study |
Trial sites expanded: 67 -> 73 locations |
| 2026-06-05 | NCT07174336 A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in… |
Trial sites expanded: 324 -> 327 locations |
| 2026-06-04 | NCT07492641 BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or… |
Trial sites expanded: 4 -> 13 locations |
| 2026-05-30 | NCT02693535 TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a… |
Trial sites expanded: 174 -> 181 locations |
| 2026-05-23 | NCT07492641 BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or… |
Recruitment opened |
| 2026-05-23 | NCT07492641 BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or… |
Trial sites expanded: 0 -> 4 locations |
| 2026-05-20 | NCT06760637 Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast… |
overall status: "Recruiting" → "Active Not Recruiting" |
| 2026-05-20 | NCT06760637 Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast… |
Trial sites reduced: 518 -> 463 locations |
| 2026-05-19 | NCT07347600 A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With… |
Trial sites expanded: 17 -> 22 locations |
| 2026-05-19 | NCT02159755 Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell… |
date change Completion pushed: 2026-12-01 -> 2027-04-30 |
| 2026-05-16 | NCT03332797 A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing… |
date change Primary completion pushed: 2026-07-31 -> 2027-07-31 |
| 2026-05-16 | NCT03332797 A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing… |
date change Completion pushed: 2026-07-31 -> 2027-07-31 |
| 2026-05-15 | NCT07174336 A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in… |
Trial sites expanded: 317 -> 323 locations |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT06380751 | Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine… | Advanced Breast Cancer | Recruiting |
| NCT04966481 | Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered… | HPV-unrelated Head and Neck Squamous Cell Carcinoma | Recruiting |
| NCT04862663 | Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer… | Locally Advanced (Inoperable) or Metastatic Breast Cancer | Recruiting |
| NCT07492641 | BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or… | HR+/HER2- Breast Cancer | Recruiting |
| NCT06065748 | A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a… | Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer | Recruiting |
| NCT07174336 | A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in… | Breast Neoplasms | Recruiting |
| NCT06377852 | The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study | Metastatic Breast Cancer | Recruiting |
| NCT07405164 | Extension Study for Participants in Studies That Include Belzutifan… | Von Hippel-Lindau Disease | Recruiting |
| NCT02513394 | PALbociclib CoLlaborative Adjuvant Study | Breast Cancer | Active, Not Recruiting |
| NCT05501886 | Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the… | Breast Cancer | Active, Not Recruiting |
| NCT02947685 | Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat… | HER-2 Positive Breast Cancer | Active, Not Recruiting |
| NCT03820830 | Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast… | Breast Cancer Recurrent | Active, Not Recruiting |
| NCT04964934 | Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m… | ER-Positive HER2-Negative Breast Cancer | Active, Not Recruiting |
| NCT04546009 | A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib… | Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer | Active, Not Recruiting |
| NCT06760637 | Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast… | Breast Cancer | Active, Not Recruiting |
| Phase 2/3 | |||
| NCT04191499 | A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs… | Breast Cancer | Active, Not Recruiting |
| Phase 2 | |||
| NCT02896335 | Palbociclib and Pembrolizumab In Central Nervous System Metastases | Metastatic Malignant Neoplasm to Brain | Recruiting |
| NCT07123090 | A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma | Recruiting |
| NCT03297606 | Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) | Lymphoma, Non-Hodgkin | Recruiting |
| NCT04841148 | Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast… | Breast Cancer | Recruiting |
| NCT04606446 | Study of PF-07248144 in Advanced or Metastatic Solid Tumors | Locally Advanced or Metastatic ER+ HER2- Breast Cancer | Recruiting |
| NCT02693535 | TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a… | Lymphoma, Non-Hodgkin | Recruiting |
| NCT04567420 | DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor… | Breast Cancer | Recruiting |
| NCT05564377 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced… | Advanced Malignant Solid Neoplasm | Recruiting |
| NCT06126276 | Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted… | Malignant Female Reproductive System Neoplasm | Recruiting |